Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	-82.35	-114.53	-122.18	-93.67	-85.47	-56.95
Depreciation & Amortization	1.56	2.06	2.22	2.03	1.76	1.94
Loss (Gain) From Sale of Assets	2.6	0.42	-0.01	-0.01	-0	-
Loss (Gain) From Sale of Investments	-	-	-	-	-0.16	-
Stock-Based Compensation	11.17	15.16	15.85	8.47	8.17	6.06
Other Operating Activities	5.1	5.32	5.33	2.35	0.26	0.51
Change in Accounts Payable	-1.05	0.17	0.16	0.84	-0.59	-0.22
Change in Unearned Revenue	-	-	7.5	-	-	-
Change in Other Net Operating Assets	-10.74	-9.84	-5.59	6.93	4.06	1.39
Operating Cash Flow	-73.7	-101.24	-96.73	-73.06	-71.98	-47.28
Capital Expenditures	-0.29	-0.62	-1.52	-1.32	-3.03	-5.46
Sale of Property, Plant & Equipment	0.56	-	0.04	0.01	0	0.17
Investment in Securities	-	-	-	-	55	-54.84
Investing Cash Flow	0.27	-0.62	-1.48	-1.32	51.97	-60.13
Long-Term Debt Issued	-	44.49	14.78	10	19.48	4.98
Long-Term Debt Repaid	-	-47.61	-	-	-15	-
Net Debt Issued (Repaid)	-8.17	-3.12	14.78	10	4.48	4.98
Issuance of Common Stock	29.2	84.78	82.76	55.47	0.51	75.95
Other Financing Activities	-0.27	-	-	-	-	-0.25
Financing Cash Flow	20.76	81.66	97.54	65.47	4.99	162.01
Foreign Exchange Rate Adjustments	0.52	-0.45	-	-	-	-
Net Cash Flow	-52.15	-20.66	-0.67	-8.91	-15.02	54.61
Free Cash Flow	-73.99	-101.86	-98.24	-74.38	-75.01	-52.74
Free Cash Flow Per Share	-8.67	-23.37	-37.14	-37.68	-46.84	-48.23
Cash Interest Paid	5.18	4.22	3.38	2.17	1.17	0.74
Cash Income Tax Paid	0.05	0.63	0.03	0.02	-	-
Levered Free Cash Flow	-43.31	-61.02	-61.1	-40.41	-46.85	-32.12
Unlevered Free Cash Flow	-39.31	-57.52	-58.79	-38.79	-46.04	-31.56
Change in Working Capital	-11.79	-9.67	2.07	7.77	3.47	1.16

Updated Nov 9, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.